ALDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aldeyra Therapeutics Inc (ALDX) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock is facing significant negative catalysts, including legal challenges, a downgraded analyst rating, and poor financial performance. Additionally, there are no strong trading signals or positive technical indicators to support a buy decision.
The MACD is positive and expanding, but RSI is neutral, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level with resistance at 1.843 and support at 1.529. Overall, the technical indicators do not suggest a strong buy opportunity.
NULL identified.
The company is facing multiple class action lawsuits alleging misleading statements about clinical trial results. Analysts have downgraded the stock, reducing the price target significantly. The FDA issued a complete response letter for its key drug candidate, reducing its probability of success.
In 2025/Q4, the company reported no revenue growth, a significant drop in net income (-59.13% YoY), and a decline in EPS (-59.26% YoY). Gross margin remained at 0%. The financial performance is weak and does not support a buy decision.
H.C. Wainwright downgraded the stock to Neutral from Buy, with a price target reduction from $10 to $2. This downgrade reflects reduced confidence in the company's drug pipeline and overall prospects.
